Home » The Clear Picture – Practical Guides » Heartburn Tablets and Your Bones
What the research really says about omeprazole, lansoprazole and the rest.
You may have read that acid reflux tablets weaken your bones. The research on this is more interesting, and a good deal more reassuring, than the headlines suggest. This guide explains what has actually been found, what it means for you, and what is worth raising at your next medication review.
People who take these tablets long term do appear to have slightly more fractures than people who do not. But when researchers have measured bone density in the same people, they have mostly found no difference. The bones do not look thinner. That combination is unusual, and it tells us that the simplest explanation, that these tablets thin your bones, is probably wrong. The extra fractures are more likely to come from who takes these tablets (people who are, on average, less well and more likely to fall) than from what the tablets do to bone. This is not a reason to stop your tablets. It is a good reason to check, once a year, that you still need them.
This guide is about a group of medicines called proton pump inhibitors, usually shortened to PPIs. They reduce the amount of acid your stomach makes, and they are among the most widely prescribed medicines in the world. You may recognise one of these names on your box:
They are prescribed for acid reflux and heartburn, for stomach and duodenal ulcers, for inflammation of the gullet, and to protect the stomach lining in people taking anti-inflammatory painkillers or certain other medicines. In some of those situations they are genuinely protective, they prevent serious bleeding, and stopping them would do considerably more harm than any effect on bone.
A second, older group of medicines does a gentler version of the same job: the histamine-2 blockers, such as famotidine, cimetidine and nizatidine. These will come up later, because comparing the two groups turns out to be the most useful thing anyone has done in this area.
In 2006 two large studies reported that people who had taken these tablets for a long time had more broken bones than people who had not. One found a 44% increase in hip fractures after a year or more of use. Others followed. A Canadian study found that seven or more years of use was linked to roughly double the risk of the kind of fracture associated with osteoporosis.
That was enough to generate headlines and a great many cautious review articles. The proposed explanation was straightforward and easy to remember: stomach acid helps you absorb calcium, these tablets reduce stomach acid, therefore they must reduce calcium absorption, therefore your bones must suffer.
It is a tidy chain of reasoning. Almost every link in it has since been tested, and most of them have broken.
This is the part that changed the picture, and it has never really reached the public.
The biggest study of its kind followed 161,806 women aged 50 to 79 in the United States for an average of nearly eight years. It did find some extra fractures in women taking these tablets. About 25% more fractures overall, and more spine and wrist fractures. But it found no extra hip fractures at all. And when the researchers scanned the women’s bones, they found that bone density in tablet-users and non-users was identical at the hip, the spine and across the whole body. Over the following years, the density of the tablet-users’ bones did not fall faster than anyone else’s.
Several other large studies have looked at the same question in the same way and reached the same conclusion: no meaningful difference in bone density, and no faster bone loss.
More fractures, but no thinner bones. Whatever is going on, it is not ordinary bone loss, and that means the usual explanation you will find online is not the right one.
This is a very good question, and it has been answered better than most questions in this area.
Oestrogen protects bone. When it falls at the menopause, bone is lost more quickly. So it would be reasonable to wonder whether these tablets only cause trouble in women who have already lost that protection, and whether HRT would therefore shield you.
The large American study mentioned above planned in advance to check exactly this. Roughly 1,600 of the women taking a stomach tablet were also taking HRT at the time. When the researchers compared women on HRT with women not on it, they found no difference in how the stomach tablets behaved. HRT neither made things worse nor protected against the effect.
A different study followed around 2,000 American women through the menopause transition for about ten years, scanning their bones repeatedly. Some of them started a stomach tablet during that time; some started one of the older histamine-2 blockers; most took neither.
The researchers did something clever. They also looked at the women who started HRT, as a test of their own methods, because HRT is known to improve bone density, so if the study could not detect that, it could not be trusted to detect anything. It detected the HRT effect exactly as expected. And in the same women, using the same methods, it detected nothing whatsoever from the stomach tablets, at the spine, the hip or the femoral neck.
That is about as clean an answer as this kind of research produces. A method proven to work on the same data found no effect.
A British study looked at more than 120,000 fractures in people aged between 4 and 29, an age group with no question of oestrogen loss at all. It found a link with fractures in the young adults, though not in the children. Whatever is happening, it is clearly not something that depends on the menopause.
So: is it the oestrogen, or is it the tablet? On the evidence, it appears to be neither, at least not in the way the question implies. Oestrogen status does not change the picture, and the tablets do not appear to be thinning bone. Something else is producing the extra fractures.
There are three serious candidates, and they are not mutually exclusive.
This is almost certainly the largest part of the answer, and it is the least discussed. In that study of 161,806 women, the ones taking a stomach tablet were, compared with everyone else:
That is a description of a group of people who are more likely to fall. And falling, not bone density, is what breaks most bones. Researchers adjust their figures to allow for these differences, but adjustment only removes the part you have measured. The rest stays in the result and looks like a drug effect.
Remarkably few studies in this area have actually counted falls. Given the picture above, this is a significant gap. A fracture needs both a fragile bone and an event that loads it. Most of the research has looked only at the first.
There is one genuinely interesting laboratory finding. Bone is built in two stages: a soft protein scaffold is laid down first, and then mineral is deposited into it to make it hard. An enzyme called PHOSPHO1 is essential to that second stage.
Researchers in Brighton and Edinburgh found that every proton pump inhibitor they tested blocks this enzyme in the laboratory and slows the hardening of bone grown in culture. The older histamine-2 blockers do not do this at all.
If this turns out to matter in real people, and that is still an open question, because laboratory concentrations are not the same as the amounts that reach your bones, it would explain the puzzle neatly. Bone that contains the normal amount of mineral but has not hardened quite properly would show up as normal on a standard bone density scan, while still being slightly easier to break. In other words, the scan everyone has been using to look for the problem may be the wrong instrument for finding it.
Please read this first. Nothing in this guide is a reason to stop a prescribed medicine. Stopping a proton pump inhibitor suddenly can cause a temporary surge of acid and a sharp return of symptoms, and in some people these tablets are preventing a dangerous stomach bleed. Any change should only be made after consulting your GP or pharmacist, and usually gradually.
With that said, here is a sensible way to think about it.
| If this is you | What is reasonable |
|---|---|
| You take a PPI short term, or now and then, for heartburn | There is no evidence of any effect on bone at this level of use. Nothing to do. |
| You have been on a PPI for years without anyone reviewing it | This is the common situation and the one worth acting on. Ask for a review, not because of your bones specifically, but because repeat prescriptions drift on by default. |
| You take a PPI to protect your stomach from anti-inflammatory painkillers or other medicines | The protection is real and well established. The right question is whether you still need the painkiller, not whether you should drop the protection. |
| You have osteoporosis or have already broken a bone, and take a PPI | Worth raising, but the evidence does not suggest the tablet is making your bones thinner. Focus on the things that are proven to help: strength and balance work, protein, calcium, vitamins D3 and K2, reviewing everything that increases your fall risk. |
| You take a PPI and are on HRT | The research specifically looked at this. HRT does not appear to change the picture either way. |
Long-term users of acid reflux tablets do have a slightly higher fracture rate, but their bone density is not lower, and the effect does not depend on the menopause or on whether you take HRT. The most likely explanations are the general health of the people who take these tablets and their higher risk of falling, possibly with a small direct effect on how bone hardens that standard scans cannot see. This is a reason to review whether you still need the tablet, and a strong reason to work on your balance and strength. It is not a reason to stop a medicine that is doing an important job.
This guide is written by the Education Directorate of IIMHE for general information and is not a substitute for advice about your own treatment. Do not start, stop or change any prescribed medicine on the basis of what you have read here. Speak to your GP or pharmacist, who knows why your tablet was started and what else you are taking. IIMHE · The Clear Picture · Practical Guides.
2nd February 2026 @ 20:00 GMT
Nutrition and musculoskeletal health
Given by: Dr Kimberley Zambito, Orthopaedic Consultant
Hosted by: Dr Nick Birch
Throughout 2026 and beyond, IIMHE (the International Institute of Musculoskeletal Health Education), in partnership with OsteoscanUK, will host a series of engaging educational webinars, open to anyone interested in bone and musculoskeletal health.